Bluebird Bio (NASDAQ: BLUE), a leader in gene therapy, could be a great pick for growth investors. This company has two gene therapies that the U.S. Food and Drug Administration (FDA) has approved: Zynteglo (betibeglogene autotemcel) and Skysona (elivaldogene autotemcel). Zynteglo is the first gene therapy for patients with beta-thalassemia, a rare blood disorder that often requires regular blood transfusions. Skysona is indicated for boys aged 4 to 17 with cerebral adrenoleukodystrophy (CALD), a rare and progressive neurological disorder.

While estimates vary, Wall Street analysts aren't overly excited about the commercial prospects of either therapy. For instance, SVB Securities analysts think Bluebird is in line to eventually haul in approximately $100 million in annual sales from both Zynteglo and Skysona. That amount won't be sufficient to push the biotech into positive free cash flow territory. However, the biotech's experimental sickle cell disease gene therapy, lovo-cel, could be a game-changer for the company.

Here's what investors need to know right now.

Continue reading

Source Fool.com